Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: Identifying dosing regimens to suppress resistance development

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 3987-3993

  Tam, Vincent H ^a   Ledesma, Kimberly R ^a   Vo, Giao ^a   Kabbara, Samer ^a   Lim, Tze Peng ^a   Nikolaou, Michael ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; GENTAMICIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; COMPUTER SIMULATION; DOSE CALCULATION; DRUG EXPOSURE; DRUG RESPONSE; HOLLOW FIBER; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARAMETER; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA;

EID: 55849103189     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01468-07     Document Type: Article

References (16)

1. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial testing: 17th informational supplement. CLSI document M100-S17. CLSI, Wayne, PA.
2. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
3. Gerber, A. U., A. P. Vastola, J. Brandel, and W. A. Craig. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691-697.
4. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
5. Higgins, P. G., H. Wisplinghoff, D. Stefanik, and H. Seifert. 2004. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J. Antimicrob. Chemother. 54:821-823.
6. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
7. Kuo, L. C., C. C. Lai, C. H. Liao, C. K. Hsu, Y. L. Chang, C. Y. Chang, and P. R. Hsueh. 2007. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 13:196-198.
8. Kwa, A. L., J. G. Low, E. Lee, A. Kurup, H. L. Chee, and V. H. Tam. 2007. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn. Microbiol. Infect. Dis. 58:99-104.
9. Nikolaou, M., A. N. Schilling, G. Vo, K. T. Chang, and V. H. Tam. 2007. Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann. Biomed Eng. 35:1458-1470.
10. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38:1279-1286.
11. Talbot, G. H., J. Bradley, J. E. Edwards, Jr., D. Gilbert, M. Scheld, and J. G. Bartlett. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
12. Tam, V. H., S. Kabbara, G. Vo, A. N. Schilling, and E. A. Coyle. 2006. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:2626-2631.
13. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51:744-747.
14. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, R. Leary, and G. L. Drusano. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.
15. Tam, V. H., A. N. Schilling, and M. Nikolaou. 2005. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J. Antimicrob. Chemother. 55:699-706.
16. Tam, V. H., A. N. Schilling, K. Poole, and M. Nikolaou. 2007. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J. Antimicrob. Chemother. 60:1302-1309.